[go: up one dir, main page]

ES2101012T3 - Derivados de acidos guanidinoalquilo-1,1-bisfosfonicos, procedimiento para su preparacion y su utilizacion. - Google Patents

Derivados de acidos guanidinoalquilo-1,1-bisfosfonicos, procedimiento para su preparacion y su utilizacion.

Info

Publication number
ES2101012T3
ES2101012T3 ES92121077T ES92121077T ES2101012T3 ES 2101012 T3 ES2101012 T3 ES 2101012T3 ES 92121077 T ES92121077 T ES 92121077T ES 92121077 T ES92121077 T ES 92121077T ES 2101012 T3 ES2101012 T3 ES 2101012T3
Authority
ES
Spain
Prior art keywords
procedure
guanidinoalkyl
derivatives
preparation
atomes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92121077T
Other languages
English (en)
Inventor
Hans-Jochen Dr Lang
Christoph Dr Naumann
Denis Carniato
Anne-Marie Moura
Ryochi Satoh
Masakazu Katoh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Application granted granted Critical
Publication of ES2101012T3 publication Critical patent/ES2101012T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4025Esters of poly(thio)phosphonic acids
    • C07F9/405Esters of poly(thio)phosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839Polyphosphonic acids
    • C07F9/3873Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503Five-membered rings
    • C07F9/6506Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65068Five-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA INVENCION DESCRIBE COMPUESTOS TAUTOMEROS DE LAS FORMULA IA, IB O IC Y/O SUS SALES FISIOLOGICAMENTE TOLERABLES, EN LAS QUE R1, R2, R3, R4, R5, R6 O R7 SON ATOMOS DE HIDROGENO, (C1 C7) STITUIDO, (C1 C4) UIDO, R2 Y R3, R3 Y R4 Y R5 FORMAN UN ANILLO SATURADO, MONOCICLICO DE 5 A 7 MIEMBROS O INSATURADO HETEROCICLICO, QUE ESTA UNA O VARIAS VECES SUSTITUIDO, R8, R9, R10 O R11 SON ATOMOS DE HIDROGENO O (C1 ROXI O HALOGENO, L Y N SON UNA CIFRA ENTERA DE 0 A 2, LA SUMA DE LAS CIFRAS L, M Y N ES MENOR O IGUAL A 10; PROCEDIMIENTO PARA LA OBTENCION DE LOS COMPUESTOS DE LAS FORMULAS IA, IB O IC, MEDICAMENTOS ASI COMO SU UTILIZACION PARA LA PROFILAXIS O EL TRATAMIENTO DE LA OSTEOPOROSIS.
ES92121077T 1991-12-12 1992-12-10 Derivados de acidos guanidinoalquilo-1,1-bisfosfonicos, procedimiento para su preparacion y su utilizacion. Expired - Lifetime ES2101012T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4140908 1991-12-12
DE4211976 1992-04-09

Publications (1)

Publication Number Publication Date
ES2101012T3 true ES2101012T3 (es) 1997-07-01

Family

ID=25910001

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92121077T Expired - Lifetime ES2101012T3 (es) 1991-12-12 1992-12-10 Derivados de acidos guanidinoalquilo-1,1-bisfosfonicos, procedimiento para su preparacion y su utilizacion.

Country Status (16)

Country Link
US (1) US5294608A (es)
EP (1) EP0546548B1 (es)
JP (1) JP3377234B2 (es)
KR (1) KR100269544B1 (es)
AT (1) ATE152453T1 (es)
AU (1) AU657018B2 (es)
BR (1) BR9204984A (es)
CA (1) CA2085171C (es)
DE (1) DE59208426D1 (es)
DK (1) DK0546548T3 (es)
ES (1) ES2101012T3 (es)
FI (1) FI105550B (es)
MX (1) MX9207215A (es)
NZ (1) NZ245414A (es)
RU (1) RU2124519C1 (es)
TW (1) TW222637B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148933A1 (en) * 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
DE4223940A1 (de) * 1992-07-21 1994-01-27 Boehringer Mannheim Gmbh Neue acyclische Amidingruppen-haltige Diphosphonsäurederivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE59309360D1 (de) * 1992-12-02 1999-03-18 Hoechst Ag Guanidinalkyl-1, 1-bisphosphonsäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung
JPH06298779A (ja) * 1993-04-15 1994-10-25 Hoechst Japan Ltd ヘテロ環イミノビスメチレンビスホスホン酸誘導体
US5854227A (en) * 1994-03-04 1998-12-29 Hartmann; John F. Therapeutic derivatives of diphosphonates
DE19546736A1 (de) * 1995-12-14 1997-06-19 Hoechst Ag Substituierte Chromanylsulfonyl(thio)harnstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Präparate
AU6452098A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
ZA981936B (en) * 1997-03-07 1999-09-06 Metabasis Therapeutics Inc Novel benzimidazole inhibitors of fructose 1,6-bisphosphatase.
IT1303672B1 (it) 1998-07-28 2001-02-23 Nicox Sa Sali nitrati di farmaci attivi nei disordini ossei
AU2756701A (en) * 2000-01-04 2001-07-16 Regents Of The University Of California, The Use of low dosage bisphosphonates to inhibit cardiac and arterial calcification
WO2008128056A1 (en) * 2004-10-08 2008-10-23 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps
WO2006039721A2 (en) * 2004-10-08 2006-04-13 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
EP2001486A4 (en) * 2006-03-17 2010-12-29 Univ Illinois BIPHOSPHONATE COMPOUNDS AND CORRESPONDING METHODS
US7457149B2 (en) 2006-05-05 2008-11-25 Macronix International Co., Ltd. Methods and apparatus for thermally assisted programming of a magnetic memory device
CN101679466A (zh) * 2007-04-12 2010-03-24 伊利诺伊大学评议会 对包括fpps、ggpps和dpps在内的多靶点效力提高的二膦酸盐化合物及方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3225469A1 (de) * 1982-07-05 1984-01-05 Schering AG, 1000 Berlin und 4709 Bergkamen Diphosphonsaeure-derivate und diese enthaltende pharmazeutische praeparate
US4812311A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
IL77243A (en) * 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
EP0243173B1 (en) * 1986-04-24 1991-06-26 Fujisawa Pharmaceutical Co., Ltd. New diphosphonic acid compounds, processes for the preparation thereof and pharmaceutical composition comprising the same
EP0282309A3 (en) * 1987-03-11 1990-03-14 Yamanouchi Pharmaceutical Co. Ltd. Azole-aminomethylene bisphosphonic acid derivatives
IL86951A (en) * 1987-07-06 1996-07-23 Procter & Gamble Pharma Methylene phosphonoalkylphosphinates and pharmaceutical preparations containing them
US4990503A (en) * 1988-08-12 1991-02-05 Yamanouchi Pharmaceutical Co., Ltd. Heterocyclic bisphosphonic acid derivatives

Also Published As

Publication number Publication date
MX9207215A (es) 1993-06-01
AU3017392A (en) 1993-06-17
CA2085171C (en) 2003-12-02
NZ245414A (en) 1995-04-27
JP3377234B2 (ja) 2003-02-17
CA2085171A1 (en) 1993-06-13
US5294608A (en) 1994-03-15
JPH05271260A (ja) 1993-10-19
BR9204984A (pt) 1993-06-15
FI925617A0 (fi) 1992-12-10
RU2124519C1 (ru) 1999-01-10
KR100269544B1 (ko) 2000-10-16
TW222637B (es) 1994-04-21
EP0546548A1 (de) 1993-06-16
ATE152453T1 (de) 1997-05-15
DE59208426D1 (de) 1997-06-05
FI105550B (fi) 2000-09-15
DK0546548T3 (da) 1997-10-13
FI925617A7 (fi) 1993-06-13
EP0546548B1 (de) 1997-05-02
AU657018B2 (en) 1995-02-23

Similar Documents

Publication Publication Date Title
ES2101012T3 (es) Derivados de acidos guanidinoalquilo-1,1-bisfosfonicos, procedimiento para su preparacion y su utilizacion.
ES2104708T3 (es) Compuestos heterociclicos terapeuticos.
ES2128791T3 (es) Derivados espirocetales, composiciones que los contienen y su uso como agentes terapeuticos.
ES2129485T3 (es) Derivados de acidos guanidinoalquil-1,1-bisfosfonicos, procedimiento para su preparacion y su utilizacion.
MX9707453A (es) Derivados de quinazolina.
GT199800180A (es) Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos.
ES2084944T3 (es) Amidas terapeuticas.
ES2054860T3 (es) Nuevos derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion, asi como a su utilizacion como medicamentos.
ES2182161T3 (es) Utilizacion de derivados de pirimidina para la preparacion de un medicamento para la prevencion del cancer.
ES2143526T3 (es) Derivados de amida que tienen actividad antihipercolesterolemica, su preparacion y sus usos terapeuticos.
ES2168487T3 (es) Derivados de n-heteroaril-piridinasulfonamida y su uso como antagonistas de la endotelina.
PA8442001A1 (es) Derivados de pirimidina biciclica condensada
CR6726A (es) Compuestos azapoliciclicos condensados con arilo
ES2094843T3 (es) Bencisotiazol- y bencisoxazol-3-carboxamidas, un procedimiento para su preparacion y su empleo como medicamentos antipsicoticos.
AR015712A1 (es) Derivados de 3,4-dihidro-tieno[2,3-d]pirimidina-3-sustituidos y su uso para la preparacion de composiciones farmaceuticas
AR015446A1 (es) Antagonistas de receptores de vitronectina, composicion farmaceutica que los contiene, procedimiento para su preparacion, su uso para la elaboracion de unmedicamento y compuestos intermediarios
AR028475A1 (es) Derivados de azaindol y uso de los mismos para la manufactura de un medicamento para el tratamiento de la depresion.
ES2121597T3 (es) Derivados de bencenosulfonamida para el tratamiento de la inestabilidad de la vejiga.
AR005102A1 (es) Compuestos derivados de octahidro-pirrolo [1,2-a]-pirazina 2,7-sustituidos, composiciones farmaceuticas y uso de dichos compuestos para la fabricacion deun medicamento.
ES2056073T3 (es) Aril-aralquil-eteres, procedimientos para su preparacion y composicion farmaceutica que los comprende.
ES2095848T3 (es) Nuevos derivados de fosfolipidos y su utilizacion para la preparacion de medicamentos antiviricos.
ES2057022T3 (es) 4,5,7,8-tetrahidro-6h-tiazolo (5,4-d) azepinas su preparacion y su utilizacion como medicamento.
ES2122221T3 (es) Compuestos terapeuticos adecuados para el tratamiento de enfermedades conectadas con la deficiencia de glutation, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
UY26329A1 (es) Antagonistas de los receptores de vitronectina
ES2178718T3 (es) Nuevos derivados de pirazoles acidos, su procedimiento de preparaacion, su aplicacion como medicamentos, su nueva utilizacion y composicion farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 546548

Country of ref document: ES